Colon Cancer, Version 1.2017 Clinical Practice Guidelines in Oncology

被引：608

作者：

Benson, Al B., III ^{[1
]}

Venook, Alan P. ^{[2
]}

Cederquist, Lynette ^{[3
]}

Chan, Emily ^{[4
]}

Chen, Yi-Jen ^{[5
]}

Cooper, Harry S. ^{[6
]}

Deming, Dustin ^{[7
]}

Engstrom, Paul F. ^{[6
]}

Enzinger, Peter C. ^{[8
]}

Fichera, Alessandro ^{[9
]}

Grem, Jean L. ^{[10
]}

Grothey, Axel ^{[11
]}

Hochster, Howard S. ^{[12
]}

Hoffe, Sarah ^{[13
]}

Hunt, Steven ^{[14
,15
]}

Kamel, Ahmed ^{[16
]}

Kirilcuk, Natalie ^{[17
]}

Krishnamurthi, Smitha ^{[18
,19
]}

Messersmith, Wells A. ^{[20
]}

Mulcahy, Mary F. ^{[1
]}

Murphy, James D. ^{[3
]}

Nurkin, Steven ^{[21
]}

Saltz, Leonard ^{[22
]}

Sharma, Sunil ^{[23
]}

Shibata, David ^{[24
]}

Skibber, John M. ^{[25
]}

Sofocleous, Constantinos T. ^{[22
]}

Stoffel, Elena M. ^{[26
]}

Stotsky-Himelfarb, Eden ^{[27
]}

Willett, Christopher G. ^{[28
]}

Wu, Christina S. ^{[29
,30
]}

Gregory, Kristina M.

Freedman-Cass, Deborah

机构：

[1] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA

[2] UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA

[3] UC San Diego Moores Canc Ctr, San Diego, CA USA

[4] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

[5] City Hope Comprehens Canc Ctr, Duarte, CA USA

[6] Fox Chase Canc Ctr, 7701 Burholme Ave, Philadelphia, PA 19111 USA

[7] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA

[8] Dana Farber Brigham & Womens Canc Ctr, Milford, MA USA

[9] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA

[10] Fred Pamela Buffett Canc Ctr, Omaha, NE USA

[11] Mayo Clin, Ctr Canc, Rochester, MN USA

[12] Smilow Canc Hosp, Yale Canc Center, New Haven, CT USA

[13] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA

[14] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA

[15] Washington Univ, Sch Med, St Louis, MO 63130 USA

[16] Univ Alabama Birmingham, Birmingham Comprehens Canc Ctr, Birmingham, AL USA

[17] Stanford Canc Inst, Stanford, CA USA

[18] Univ Hosp Seidman Canc Ctr, Case Comprehens Canc Center, Cleveland, OH USA

[19] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[20] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA

[21] Roswell Pk Canc Inst, Buffalo, NY 14263 USA

[22] Mem Sloan Kettering Canc Ctr, 1275 York Ave, New York, NY 10021 USA

[23] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA

[24] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA

[25] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[26] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA

[27] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA

[28] Duke Canc Inst, Durham, NC USA

[29] Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc, Columbus, OH 43210 USA

[30] Solove Res Inst, Columbus, OH USA

来源：

JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK | 2017年 / 15卷 / 03期

关键词：

METASTATIC COLORECTAL-CANCER; GROWTH-FACTOR RECEPTOR; PHASE-III TRIAL; KRAS WILD-TYPE; CETUXIMAB PLUS IRINOTECAN; HIGH-DOSE LEUCOVORIN; 1ST-LINE COMBINATION CHEMOTHERAPY; OXALIPLATIN-BASED CHEMOTHERAPY; POSTPROGRESSION SURVIVAL-TIME; MONOCLONAL-ANTIBODY THERAPY;

D O I：

10.6004/jnccn.2017.0036

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

This portion of the NCCN Guidelines for Colon Cancer focuses on the use of systemic therapy in metastatic disease. Considerations for treatment selection among 32 different monotherapies and combination regimens in up to 7 lines of therapy have included treatment history, extent of disease, goals of treatment, the efficacy and toxicity profiles of the regimens, KRAS/NRAS mutational status, and patient comorbidities and preferences. Location of the primary tumor, the BRAF mutation status, and tumor microsatellite stability should also be considered in treatment decisions.

引用

页码：370 / 398

页数：29

共 242 条

[1]

Survival, safety, and prognostic factors for outcome with Regorafenib in patients with metastatic colorectal cancer refractory to standard therapies: results from a multicenter study (REBACCA) nested within a compassionate use program [J].

Adenis, Antoine ;

de la Fouchardiere, Christelle ;

Paule, Bernard ;

Burtin, Pascal ;

Tougeron, David ;

Wallet, Jennifer ;

Dourthe, Louis-Marie ;

Etienne, Pierre-Luc ;

Mineur, Laurent ;

Clisant, Stephanie ;

Phelip, Jean-Marc ;

Kramar, Andrew ;

Andre, Thierry .

BMC CANCER, 2016, 16

[2]

Extended RAS Gene Mutation Testing in Metastatic Colorectal Carcinoma to Predict Response to Anti-Epidermal Growth Factor Receptor Monoclonal Antibody Therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015 [J].

Allegra, Carmen J. ;

Rumble, R. Bryan ;

Hamilton, Stanley R. ;

Mangu, Pamela B. ;

Roach, Nancy ;

Hantel, Alexander ;

Schilsky, Richard L. .

JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02) :179-+

[3]

Phase III Trial Assessing Bevacizumab in Stages II and III Carcinoma of the Colon: Results of NSABP Protocol C-08 [J].

Allegra, Carmen J. ;

Yothers, Greg ;

O'Connell, Michael J. ;

Sharif, Saima ;

Petrelli, Nicholas J. ;

Colangelo, Linda H. ;

Atkins, James N. ;

Seay, Thomas E. ;

Fehrenbacher, Louis ;

Goldberg, Richard M. ;

O'Reilly, Seamus ;

Chu, Luis ;

Azar, Catherine A. ;

Lopa, Samia ;

Wolmark, Norman .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (01) :11-16

[4]

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer [J].

Amado, Rafael G. ;

Wolf, Michael ;

Peeters, Marc ;

Van Cutsem, Eric ;

Siena, Salvatore ;

Freeman, Daniel J. ;

Juan, Todd ;

Sikorski, Robert ;

Suggs, Sid ;

Radinsky, Robert ;

Patterson, Scott D. ;

Chang, David D. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) :1626-1634

[5]

Amin MB., 2016, AJCC Cancer Staging Manual, V8th

[6]

CPT-11 (irinotecan) addition to bimonthly, high-dose leucovorin and bolus and continuous-infusion 5-fluorouracil (FOLFIRI) for pretreated metastatic colorectal cancer [J].

André, T ;

Louvet, C ;

Maindrault-Goebel, F ;

Couteau, C ;

Mabro, M ;

Lotz, JP ;

Gilles-Amar, V ;

Krulik, M ;

Carola, E ;

Izrael, V ;

de Gramont, A .

EUROPEAN JOURNAL OF CANCER, 1999, 35 (09) :1343-1347

[7]

[Anonymous], 2015, OPDIVO PACK INS

[8]

[Anonymous], 2016, ZALTRAP PACK INS

[9]

[Anonymous], VECT PACK INS

[10]

[Anonymous], 2016, KEYTRUDA PACK INS

← 1 2 3 4 5 6 7 8 9 10 →